Peter Vranes, Nutromics - Continuous Molecular Monitoring | LSI USA '24

Peter Vranes  0:04  
So I'm Peter Vranes, CEO, co founder of Nutromics, and we exist as a company to save millions of lives through continuous diagnostic monitoring. So how are we going to do that? Well, we have a medical wearable device, it looks like that. It's our prototype device. And it has micro needles. And on the tips of those micro needles, we put our DNA based sensor. And that sensor is a platform technology that monitors any diagnostic in real time. And we also have our launch device, which I have in my hand here, which is a pared back version of that, that we'll be launching in a couple of years. So a few quick facts about new training. We're a medical diagnostics company, world leading DNA based sensing technology. We're clinical stage, we've played our first in human studies last year, commercializing in a couple of years, we've raised $35 million. Notable investor is Dexcom, post money, val of 200. Mil on our last round, which was late last year, we have a very large Tam and a willing team of 57. based in Melbourne, Australia and San Diego, let's go to the core problem that we're tackling. And that is that lab diagnostics today provide only a single data point of where a patient was several hours prior. So let's go through how this works. So a test gets ordered, a blood draws taken, it's sent to the lab where it's processed. And then the Clichy gets a single data point of where that patient was when the blood draw took place several hours ago. Now, 70% of all clinical decisions are based on lab diagnostics like this. And for a lot of diagnostic targets that don't move very much. They're quite static, that's fine. But there are there are hundreds of diagnostic targets that are dynamic, they're changing rapidly. So a clinician doesn't know whether they're trending up flat or down. So what do they do, they have to take another blood draw, and they repeat that process. And we know in reality, that just simply doesn't happen. It's too expensive. They don't have the time. And unfortunately, that cost lives and it costs billions of dollars in hospital inefficiency. So our solution to the problem is continuous real time diagnostic monitoring. So our device replaces the blood draw the sample delivery, the sample analysis and the single data point. And it's what we call, in effect a lab on a patch. And it's quite remarkable when you think about all the infrastructure and process that goes into every hospital in the labs and all those hospitals, we replaced that with a simple solid state device that does it continuously. And in real time. Now we put together a one minute animation that kind of puts all this together. So in the ICU, patients getting dosed the drug, and when we go into the interstitial fluid, which is where we operate, same fluid, that CGM is operating. These are their micro needles. And on the tip of those micro needles, we have our DNA base sensor. So it looks like a ribbon like that very selective towards target. So you see certain targets come along, doesn't respond target of interest now comes along vancomycin, it recognizes that it's a shape changes signal change, we can measure that it releases it out the left, which is what allows to be continuous. Each one of those micro needles is a separate sensor. So we've got the world's only wearable tech that can do multi analyte sensing signal goes out through a Bluetooth gateway, out into the cloud, and then back onto onto pre existing screens. So a very simplistic way, that's how all of this gets put together. So most of you will be familiar with continuous glucose monitors $10 billion per year revenue market, growing at double digits, and we are the evolution of that technology. That technology is based on enzymatic sensing, which is not a platform and our technology, DNA base sensing is a is a platform. So let's have a look at this timeline because it tells a story. So in the last 40 years, there's only ever been six enzymatic sensors that have been developed and shown to work on body. Now compare that to what we've done in the last six years, we've more than doubled what the whole Intermatic industry took 40 years to do. We did that in less than six. That's the power of a platform. And then secondly, those six enzymatic sensors are all metabolites. So things endogenous in our body, that's the only class of target they can they can go after. Whereas we don't have that limitation. We can do metabolites. We can do drugs, proteins, hormones, so we can do any diagnostic target continuously in real time. So it begs the question if you can monitor anything continuously and in real time, what problems in healthcare you're going to solve. So we've thought long and hard about that over quite some time. And we're starting with therapeutic drug monitoring. of the antibiotic vancomycin. So vancomycin is used for sepsis. And MRSA has a narrow therapeutic window and high toxicity, very difficult to dose this drug, it's number one dose, that IV antibiotic in the world, one in six of all inpatients get this drugs and very common, and it's a $3 billion market for us. So you can get a bit of an idea of why we started here. What's the problem? Well, if we go back to the original core problem, delayed and limited data and a cost lives, so they do what's called trough based dosing, typically, you get vancomycin for seven days. But for the first two days, there is no monitoring of the drug whatsoever, while they get into the patient into what's called steady state. And then after that, they get two doses of the drug a day, and they get what's called a trough dose. Now, this is what they actually say they don't see all those lines continuously, they just say these data points, and they get very little inflammation, and it's delayed. The consequence of that is that after 43% of patients can acute kidney injury, and a third of them dime. Obviously, clinicians are very worried about toxicity. So they're conservative in their dosing, that has another problem. And that is under dosing. So remember, we're talking about life threatening bacterial infections here. So under dosing increases, hospital stay, and each night in the ICU is another $3,000. So we're going to solve that problem by continuously monitoring with this device vancomycin from the first dose. So we'll help clinicians get that patient into the therapeutic range quickly, and keep them there outside the toxic range. So this is a video that you're seeing out for a clinical trial that we did last year. And this is the application of the patch onto a patient that's receiving vancomycin. And what you're witnessing here is the world's first monitoring of a drug continuously and in real time and a human. So that was a major milestone for us. And we think the industry as well. So we're all about outcomes, you want to drive to improve outcomes. And those outcomes are a reduction in acute kidney injury that costs $15,000, on average, per patient, shorten hospital stays, and reduce mortality. This year, we're moving into the intended use population in the ICU. So we're doing clinical studies in a number of geographies in the US, Asia, and Europe. And we're also doing clinical studies for device optimization. Now, the patches I mentioned before, can do multi analyte sensing. And we are in effect a platform on a platform on a platform. So what do I mean by that? Well, the patch itself is a platform. So as we add additional sensors, we're adding them to the same to the same patch. So we're starting off with vancomycin going to create noon and beyond. But it doesn't end there. Because the actual electronics in the firmware have been designed for multi analyte sensing, the sensor itself, we are very vertically integrated. So we can just go from design to a sensor on a body in approximately four weeks very quickly. And the manufacturing processes also designed for multi product variants. So all of this leads to a really unprecedented ability to have rapid product deployment and go after major revenue opportunities. So how are we going to roll this out? So we started with therapeutic drug monitoring of vancomycin, and then we're going to go further down that that drug vertical. Beyond that, we're moving to kidney application. So sensors for renal, beyond renal, we then moving to sepsis, and then the cardiac market. And as you can see here, we're talking about very, very significant term opportunities that will be tapping into funding and milestones. So as I mentioned, we've raised 35 million to date, we've got a $10 million round, that we'll be opening shortly. Then we'll be moving next year to our series B which will be circa $30 million. And that'll get us to commercialization in two years time. That'll be outside of the US. And then moving beyond that, we'll be going towards our C round D round, and then launch in the US in 28. Thank you very much